Lead Product(s) : Caffeine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Caffeine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosuvastatin Calcium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Rosuvastatin Calcium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $12.2 million
Deal Type : Series B Financing
Boehringer, Novo-backed German biotech banks €11M in liver regeneration push
Details : The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $12.2 million
Deal Type : Series B Financing
Lead Product(s) : Hepaxa
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hepaxa Management of Non-alcoholic Fatty Liver Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 11, 2019
Lead Product(s) : Hepaxa
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 05, 2016
Lead Product(s) : Omega-3
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable